Radx tech 2 project number 13139 palogen innovative ultra-fast chip technology for covid-19 RNA detection
Ended Definitive Contract Awarded Last action
- Contract number
- 75N92021C00025
- Awardee
-
Palogen, Inc. UEI RGQTLPFQ7TG6
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,500,000
Award facts
- Contract value 100% obligated
- $1,500,000.00 Current and potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Not Competed · 1 offer Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- South Korea
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | $0 | |
| Terminate for Convenience | -$6,500,000 | |
| Other Administrative Action | $0 | |
| Definitize Letter Contract | $4,800,000 | |
| Original award | $3,200,000 |
About this award
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1.5 million firm fixed-price contract to Palogen, Inc. on September 30, 2021, for the RADX Tech 2 Project Number 13139. This definitive contract supports the development of innovative ultra-fast chip technology for COVID-19 RNA detection, with work performed in South Korea. The contract was completed on September 29, 2023, and no small business set-aside was utilized for this award.
Palogen's technology development effort aligns with the NHLBI's participation in the Rapid Acceleration of Diagnostics (RADx) initiative, a coordinated federal program launched to accelerate diagnostic testing for COVID-19. The RADx Tech component specifically focuses on supporting the development of novel diagnostic technologies and platforms that can rapidly identify COVID-19 cases. This award reflects the government's investment in advancing point-of-care and rapid diagnostic capabilities during the pandemic response period.
Quick answers
Who was awarded contract 75N92021C00025?
75N92021C00025 was awarded to Palogen, Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on September 30, 2021.
How much is contract 75N92021C00025 worth?
The government has obligated $1,500,000 on 75N92021C00025.
Was contract 75N92021C00025 competed?
The extent of competition for 75N92021C00025 was not competed. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award